Recent Updates
Recently added Catalysts

Brodalumab

Phase 4FDA approved

Psoriatic Arthritis | Biologics | Immunology |Bausch Health Companies Inc.|Trials Updated: May 13, 2026

Brodalumab development status

FDA approval on record Feb 15, 2017 as Siliq
Approval holderValeant Luxembourg
ApplicationBLA761032
Highest phase Phase 4 (NCT03240809)
Phase scored for BHCPhase 3
Registered trials 15 across 3 sponsors since Oct 2008

Label indication SILIQ ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. FDA label

Brodalumab target and mechanism

Molecular targetIL17RA
Target classAntagonist
ModalityBiologics

Also known as SILIQ, AMG 827

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials4
Total Enrollment671

FDA Designations

No designations recorded

Brodalumab clinical trials

Brodalumab · 4 trials · 20 indications

Phase 3 1Phase 1 3
NCT02024646Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic ArthritisPsoriatic Arthritis
COMPLETED484 Analytics
PHASE3COMPLETED
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Psoriatic ArthritisUnlock trial analytics

Study Endpoints

Primary Endpoints

ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16
Baseline and 16 Weeks

ACR20 is used as a measurement of the proportion of subjects who are reaching a 20% improvement of tender an swollen joint counts. The higher percent of subjects reaching a higher improvement percentage shows greater success.

Number of Adverse Events
Up to 36 weeks

The number of adverse events of each grade that occur and the number of adverse events attributed to brodalumab, as per the Common Terminology Criteria for Adverse Events version 5 (CTCAE v5).

Percentage of primary Immune-Related Adverse Event (irAE) severity decreased
24 weeks

The percentage of patients whose primary irAE severity decreased by \>1 grade per CTCAE criteria from study completion to treatment discontinuation.

Pharmacokinetic Parameters for the Maximum Amount of Observed Brodalumab Concentration for Treatment A and Treatment B.
60 days

Pharmacokinetic parameter estimates after a 210 mg dose of brodalumab, and after two 210 mg doses of brodalumab delivered subcutaneously as a single prefilled syringe (PFS) injection

Area Under the Drug Concentration Time Curve From Zero to the Time of Last Quantifiable Concentration of Brodalumab
60 days

Pharmacokinetic parameter estimates after a 210 mg dose of brodalumab, and after two 210 mg doses of brodalumab delivered subcutaneously as a single prefilled syringe (PFS) injection

The Maximum Observed Concentration of Midazolam After a Single Dose of Brodalumab
Day 1 to day 9

Midazolam pharmacokinetic parameter estimates after single oral dose of Midazolam 2 mg on Day 1 and Day 9 and a single administration of Brodalumab 210 mg on Day 2 with PK sampling collected on Day 30

The Area Under Drug Concentration Time Curve From Zero to Infinity (AUCinf)
Day 1 to Day 9

Midazolam pharmacokinetic parameter estimates after single oral dose of Midazolam 2 mg on Day 1 and Day 9 and a single administration of Brodalumab 210 mg on Day 2 with PK sampling collected on day 30

The Area Under the Drug-concentration Curve of Midazolam After a Single Dose of Brodalumab From Zero Tot he Last Time of Quantifiable Concentration
Day 1 to Day 9

Midazolam pharmacokinetic parameter estimates after single oral dose of Midazolam 2 mg on Day 1 and Day 9 and a single administration of Brodalumab 210 mg on Day 2

Secondary Endpoints

Percentage net decrease in the average steroid dose required for irAE management
Up to 36 weeks
Proportion of Patients Successfully Tapered Off Steroids
Up to 36 weeks
Mean Time to Complete Resolution of irAE Symptoms
Up to 36 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
210 mg brodalumabEXPERIMENTALAdministered via subcutaneous injections.
140 mg brodalumabEXPERIMENTALAdministered via subcutaneous injection.
PlaceboPLACEBO_COMPARATORAdministered via subcutaneous injection until week 24.
brodalumab to treat irAEs in patient with solid tumorsEXPERIMENTALBrodalumab 210 mg subcutaneous injection on weeks 0, 1, 2 followed by administration every 2 weeks until week 24
Brodalumab (single 1.5mL pre-filled syringe)EXPERIMENTALA single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection
Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL])EXPERIMENTALA single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections
Brodalumab 140mg SCEXPERIMENTALopen label, all subjects receive brodulamab
Midazolam (MDZ) 2mg oral, Brodalumab 210mg SCEXPERIMENTALMDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2)

Interventions

NameTypeDescription
210 mg brodalumabDRUG210 mg brodalumab administered via subcutaneous injection.
140 mg brodalumabDRUG140 mg brodalumab administered via subcutaneous injection.
PlaceboDRUGPlacebo administered via subcutaneous injection until week 24.
BrodalumabDRUGBrodalumab 210 mg subcutaneous injection
CT scanRADIATIONCT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites103

Inclusion Criteria: Subjects has a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis criteria (CASPAR), with ≥ 3 tender and ≥ 3 swollen joints (excluding distal interphalangeal joints). Subjects must have at least 1 psoriatic skin lesion. Exclusion Criteria: • -Subjec...

Countries:United StatesCanadaFranceGermanyGreeceHungaryLatviaMexicoPolandRussiaAustraliaNew Zealand
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMNov 10, 2026NCT06673329primaryCompletionDate: changed

Frequently asked questions about Brodalumab

What is brodalumab?

Brodalumab is an investigational biologic developed by Bausch Health Companies Inc. (ticker BHC). It is being studied in oncology and immunology settings, including breast cancer, psoriasis, and psoriatic arthritis. Brodalumab is a large-molecule biologic rather than a small-molecule drug.

What does brodalumab target?

Brodalumab targets IL17RA, the interleukin-17 receptor A. It acts as an antagonist at this receptor, blocking signaling through the IL-17 pathway. This receptor-level mechanism distinguishes brodalumab from agents that bind the IL-17 ligand itself.

Who makes brodalumab?

Brodalumab is developed by Bausch Health Companies Inc., which trades under the ticker BHC. The company is associated with the clinical development program covering the drug's oncology and immunology indications, including breast cancer, psoriasis, and psoriatic arthritis.

What phase is brodalumab in?

Brodalumab is in Phase 1 development according to its current program status. It is investigational and is being evaluated in clinical trials rather than positioned as an approved therapy. Its studied indications include breast cancer, psoriasis, and psoriatic arthritis.

What clinical trials is brodalumab in?

Brodalumab trials include NCT06673329, a recruiting Phase 1 study of brodalumab in immune-related adverse events across multiple solid tumors, and NCT02173392, a completed Phase 1 bioequivalence study in psoriasis. A completed Phase 3 study, NCT02024646, evaluated brodalumab in psoriatic arthritis with 484 participants.